Clinical Trial

Disease: B-Cell Non-Hodgkin Lymphoma, NHL, (NCT05332054)

Disease info:

B-cell lymphoma refers to types of non-Hodgkin lymphoma that are characterised by abnormalities of the "B cells" (a type of white blood cell that makes antibodies to help fight infection). The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms. 

Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. NHL is a term that's used for many different types of lymphoma that all share some of the same characteristics. NHL usually starts in lymph nodes or other lymph tissue, but it can sometimes affect the skin. Non-Hodgkin lymphoma is one of the most common cancers in the United States, accounting for about 4% of all cancers. 

 

 

Frequency:
B-cell NHL is the most common type of non-Hodgkin lymphoma. NHL accounts for about 4% of all cancers in the U.S. The American Cancer Society estimates 80,550 people will be diagnosed with NHL in 2023.
Official title:
A Study to Evaluate Long-Term Safety of CAR-T Cell Therapy in Patients With Hematologic Malignancies
Who:
Sponsor:

Caribou Biosciences, Inc.

Partners:
Locations:

United States, Arizona

Honor Health Research Institute, Scottsdale, Arizona, United States, 85258

 

United States, California

University of California Irvine, Irvine, California, United States, 92868

University of California San Diego, La Jolla, California, United States, 92093

 

United States, Florida

AdventHealth Medical Group Blood & Marrow Transplant at Orlando, Orlando, Florida, United States, 32804


United States, Georgia Locations

Blood & Marrow Transplant Group of Georgia, Atlanta, Georgia, United States, 30342

Augusta University/Georgia Cancer Center, Augusta, Georgia, United States, 30912


United States, Iowa

University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States, 52242


United States, Kentucky

Norton Cancer Institute, Louisville, Kentucky, United States, 40207


United States, New Jersey 

Atlantic Health System Cancer Care, Morristown, New Jersey, United States, 07960

 

United States, New York

Icahn School of Medicine at Mt. Sinai, New York, New York, United States, 10029

 

United States, Ohio

Oncology Hematology Care, Cincinnati, Ohio, United States, 45242

 

United States, Tennessee 

Sarah Cannon Research Institute - TriStar Health, Nashville, Tennessee, United States, 37203


United States, Texas

Baylor Research Institute, Dallas, Texas, United States, 75246

MD Anderson Cancer Center, Houston, Texas, United States, 77030


United States, Utah 

Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States, 84112

Study start:
Mar. 16, 2022
Enrollment:
150 participants
Gene editing method:
CRISPR-Cas
Type of edit:
Gene knock-out
Gene:
Programmed Cell Death 1 (PD1), T Cell Receptor (TCR), CD19-specific CAR
Delivery method:
- Ex-vivo
Trial link:
https://clinicaltrials.gov/ct2/show/NCT05332054
Safety updates:

(12-07-2021) Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

(08-09-2020) Caribou Biosciences Announces FDA Clearance of its IND for CB-010, an Off-the-shelf Allogeneic Anti-CD19 CAR-T Cell Therapy

Note:
Undisclosed
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Enrolling by invitation

Description

This is a non-interventional, long-term safety study of allogeneic CAR-T cell therapy in patients who have participated in a prior Caribou-sponsored clinical study, in a special access program, or in another study such as an IIT. The purpose of this 15-year research study is to collect long-term observational data to identify and understand potential late side effects in these patients.

Last updated: Jan. 18, 2025
close
Search CRISPR Medicine